CHRISTOPHER CANO - 22 Sep 2021 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Role: Chief Operating Officer
Signature: /s/ Christopher Cano, by Kirk Allen Coleman, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 22 Sep 2021
Net transactions value: $0
Form type: 4
Filing time: 24 Sep 2021, 16:15:29 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TFFP	Stock Option (Right to Buy)	Award	$0	+43,000	+27%	$0.000000	200,000	22 Sep 2021	Common Stock	43,000	$7.93	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Options are granted under TFF Pharmaceuticals, Inc. 2021 Stock Incentive Plan ("Plan") and the exercise of the Options is subject to stockholder approval of the Plan. Subject to stockholder approval of the Plan, each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on September 22, 2022 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on December 22, 2022.

Content

The Options are granted under TFF Pharmaceuticals, Inc. 2021 Stock Incentive Plan ("Plan") and the exercise of the Options is subject to stockholder approval of the Plan. Subject to stockholder approval of the Plan, each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on September 22, 2022 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on December 22, 2022.